MeiraGTx Holdings (MGTX) Total Non-Current Liabilities (2017 - 2025)
MeiraGTx Holdings (MGTX) posted Total Non-Current Liabilities of $248.8 million for Q4 2025, up 8.82% on a QoQ basis from $228.7 million in Q3 2025, and up 24.97% year-over-year from $199.1 million in Q4 2024.
MeiraGTx Holdings (MGTX) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
MeiraGTx Holdings' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $248.8 million for Q4 2025.
- Quarterly Total Non-Current Liabilities rose 24.97% year-over-year to $248.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $248.8 million (up 24.97% YoY) and the FY2025 annual result came in at $248.8 million, up 24.97% from the prior year.
- Total Non-Current Liabilities was $248.8 million for Q4 2025 at MeiraGTx Holdings, up from $228.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $248.8 million in Q4 2025 and bottomed at $108.4 million in Q2 2022.
- A 5-year average of $173.0 million and a median of $184.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slipped 9.03% — and 2023, when it soared 70.16%.
- MeiraGTx Holdings' Total Non-Current Liabilities stood at $132.7 million in 2021, then soared by 49.47% to $198.3 million in 2022, then retreated by 6.13% to $186.2 million in 2023, then increased by 6.95% to $199.1 million in 2024, then increased by 24.97% to $248.8 million in 2025.
- Business Quant data shows MGTX's Total Non-Current Liabilities at $248.8 million in Q4 2025, $228.7 million in Q3 2025, and $194.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | MeiraGTx Holdings | 973.21 Mn | 907.27 Mn | - | 248.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 248.82 Mn |
| Sep 30, 2025 | 228.66 Mn |
| Jun 30, 2025 | 194.30 Mn |
| Mar 31, 2025 | 189.57 Mn |
| Dec 31, 2024 | 199.10 Mn |
| Sep 30, 2024 | 200.87 Mn |
| Jun 30, 2024 | 184.12 Mn |
| Mar 31, 2024 | 185.06 Mn |
| Dec 31, 2023 | 186.17 Mn |
| Sep 30, 2023 | 172.99 Mn |
| Jun 30, 2023 | 184.44 Mn |
| Mar 31, 2023 | 195.68 Mn |
| Dec 31, 2022 | 198.32 Mn |
| Sep 30, 2022 | 176.66 Mn |
| Jun 30, 2022 | 108.39 Mn |
| Mar 31, 2022 | 124.30 Mn |
| Dec 31, 2021 | 132.68 Mn |
| Sep 30, 2021 | 113.58 Mn |
| Jun 30, 2021 | 119.15 Mn |
| Mar 31, 2021 | 117.03 Mn |